Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.

No abstract is available for this paper.

• Publication year

  2022

• Venue

  American Journal of Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 35141016PMCID PMC8822290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SHP2 Inhibition Benefits Epidermal Growth Factor Receptor mutated Non-Small Cell Lung Cancer Therapy.

  2020cited by this paper
• Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing TsMHC-II-mediated Immune Recognition.

  2020cited by this paper
• Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

  2020cited by this paper
• NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma

  2020cited by this paper
• EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

  2020cited by this paper
• Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

  2020cited by this paper
• SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer

  2020cited by this paper
• T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells

  2020cited by this paper
• Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain–Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma

  2020cited by this paper
• The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition

  2019cited by this paper
• Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer.

  2019cited by this paper
• Targeting SHP2 as a promising strategy for cancer immunotherapy.

  2019cited by this paper
• Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies

  2019cited by this paper
• SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors

  2019cited by this paper
• Cancer statistics, 2019

  2019cited by this paper
• Targeting the ERK Signaling Pathway in Melanoma

  2019cited by this paper
• Molecular Alterations in Thyroid Carcinoma.

  2019cited by this paper
• Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands

  2019cited by this paper
• Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

  2019cited by this paper
• The RAS-MAPK pathway in neuroblastoma

  2019cited by this paper
• Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma.

  2018cited by this paper
• Novel targeted therapies and immunotherapy for advanced thyroid cancers

  2018cited by this paper
• BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines

  2018cited by this paper
• Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

  2018cited by this paper
• Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

  2018cited by this paper
• SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

  2018cited by this paper
• SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.

  2018cited by this paper
• RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

  2018cited by this paper
• Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013

  2017cited by this paper
• The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies

  2017cited by this paper
• Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment

  2016cited by this paper
• Functions of Shp2 in cancer

  2015cited by this paper
• Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma.

  2015cited by this paper
• Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.

  2014cited by this paper
• Adaptive resistance to targeted therapies in cancer.

  2013cited by this paper
• Central role of RET in thyroid cancer.

  2013cited by this paper
• Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

  2012cited by this paper
• Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

  2012cited by this paper
• MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

  2012cited by this paper
• Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

  2012cited by this paper
• Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

  2011cited by this paper
• BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

  2010influential reference
• V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

  2009cited by this paper
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

  2009cited by this paper
• Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

  2007cited by this paper
• BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.

  2007cited by this paper
• Protein-tyrosine phosphatases and cancer

  2006cited by this paper
• Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

  2006cited by this paper
• Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

  2006cited by this paper
• RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.

  2006cited by this paper
• Cancer statistics

  1989cited by this paper
• The University of Bradford Institutional Repository

  year unknowncited by this paper

• Dual inhibition of BRAF for cancer treatment: advances and therapeutic potential.

  2025cites this paper
• SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway

  2025cites this paper
• SHP2 is a multifunctional target in anaplastic thyroid carcinoma: Cell intrinsic and immune-dependent anti-tumor effects.

  2025cites this paper
• PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs

  2024cites this paper
• Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

  2024cites this paper
• Targeted therapy for head and neck cancer: signaling pathways and clinical studies

  2023cites this paper
• Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis

  2023cites this paper
• MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data

  2023influential citation